Clinical Trials · NCT01630967
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- British Columbia Cancer Agency
- Enrollment
- 0
- Start date
- Aug 2012
- Locations
- 1 site, Canada
- Primary endpoint
- 50% fall in PSA